Document is current

Article History

Received: 19 May 2024

Accepted: 15 November 2024

First Online: 2 December 2024

Declarations

:

: The authors declare that they have no competing interests.

: Eligible patients were consented under the University of Arizona Institutional Review Board (IRB)-approved Flutamide trial (NCT00699907), the University of Arizona Cancer Center Tumor Biorepository (NCT00896935), and/or the HR/LR translational study (UACC IIT Continued Recruitment of High-Risk and Low-Risk Control Subjects to Assess Biomarkers of Ovarian Cancer Risk, IRB 1504771536). Together, these 3 studies comprise the Flutamide Correlative Study. These projects have been reviewed and approved by the University of Arizona IRB or designee. All documents referenced have been reviewed and approved. The University of Arizona maintains a Federal-wide Assurance (FWA) with the Office for Human Research Protections (OHRP) (FWA #00004218). This Institution assures that all of its activities related to human subjects research, regardless of the source of support, will be guided by the Belmont Report and applicable regulations according to 45 CFR 46.111 and/or 21 CFR Part 50. Informed consent was obtained from all subjects and/or their legal guardian(s).

: Not applicable.